Home / Knowledge hub /
Powering every breath you give: Our world-class Loughborough site
April 17, 2026
Pulmonary drug delivery is undergoing a period of rapid change. Developers must bring increasingly complex therapies to market while preparing inhalers for the transition to low-Global Warming Potential (GWP) propellant technologies.
Success depends on having expertise across formulation, device integration and scalable manufacturing capabilities.
Kindeva’s Loughborough, UK facility stands ready for this evolution. Our global centre of excellence for metered-dose inhalers (MDIs) combines expertise in advanced formulation labs, analytical capabilities and commercial filling infrastructure in one integrated environment.
This integrated environment supports programs from early feasibility to commercial supply. Formulation expertise, device engineering and scalable filling capabilities work together to help developers advance pulmonary therapies while preparing inhalers for the transition to low-GWP.
The result is a platform designed to simplify development, reduce risk and support the future of sustainable inhalation therapies.
In this eBook, you’ll learn:
- How Kindeva’s Loughborough site delivers comprehensive MDI development and manufacturing services.
- What makes the facility uniquely equipped to support low-GWP reformulation programs.
- Why integrated device, formulation and filling capabilities matter more than ever.
- How this facility is shaping the future of sustainable, scalable pulmonary therapies.
Download the eBook to explore how Kindeva’s Loughborough center of excellence supports scalable pulmonary development and commercial manufacturing, and how it is helping shape the future of sustainable inhalation therapies.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Meeting the challenges of fill finish manufacturing
How flexible infrastructure and early manufacturing expertise can help drug developers respond to changing demand With rising demand for glucagon-like peptide-1 (GLP-1) medicines, continued progress in biologics and the expansion of self-administered treatments, new expectations are being placed on sterile fill finish operations. Manufacturers must accommodate different container formats and production volumes while maintaining consistent […]
Learn More
Can one quality system manage complexity across multiple drug delivery platforms?
As drug development portfolios expand across multiple delivery platforms, increasing complexity places quality systems under greater strain. For sponsors considering a CDMO, it is essential to know that the Quality Management System (QMS) can provide consistency while allowing teams to respond appropriately to the requirements of each product. A harmonized QMS can provide that framework […]
Learn More
Parenteral precision: Upstream formulation handling before sterile fill finish
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. In our first blog, we explored how sterile fill finish operations are designed around […]
Learn More
Delivering tomorrow’s injectables, today
Injectable therapies are entering a new phase of complexity. Biologics, personalized medicines and combination products are increasing demand for delivery systems that must adapt to more diverse formats and patient needs. Expectations around speed and compliance also continue to rise across the development lifecycle, placing greater pressure on how these systems are designed and scaled. […]
Learn More
Green propellants and the future of metered dose inhalers
The transition to next-generation propellants (NGPs) with low global warming potential (GWP) is redefining what success looks like for pressurized metered dose inhalers (MDIs). As sustainability targets tighten, developers must rethink how inhaled therapies are formulated, tested and manufactured without compromising performance. Reformulating with NGPs affects not only the drug product but also its interaction […]
Learn More
Q&A: Navigating tech transfer and production pitfalls
Successful tech transfer alignment requires robust risk management and precise operational planning. When communication gaps or unforeseen supply chain hurdles emerge, project timelines and product quality are often the first to be affected. In this Q&A, we explore the common pitfalls of pharmaceutical tech transfers, including how to protect critical milestones without compromising safety and […]
Learn More
Webinar | Beyond the filling suite: How modular facility design supports sterile manufacturing success
Sterile manufacturing requirements are fast evolving, which means that many organizations are reassessing whether their legacy facilities can support future operational and regulatory demands. In this webinar, John Wichelt, Vice President and General Manager at Kindeva’s Bridgeton site, explores what a modern sterile fill finish facility needs to look like in this new era. Drawing […]
Learn More
What does Annex 1 mean for sterile drug product manufacturing?
Annex 1 compliance remains a key priority for companies working in sterile drug product manufacturing. But recognizing how fundamentally expectations around sterility assurance have changed may be the most significant challenge companies face. Revisions to the EU GMP Annex 1 requirements now move beyond individual compliance activities and place greater emphasis on how contamination risks […]
Learn More
Delivering value beyond manufacturing in nasal drug delivery
Nasal drug delivery has moved far beyond familiar allergy sprays, now supporting life-saving rescue therapies, complex systemic treatments and investigational nose-to-brain approaches. As this evolution and shift toward wider, more complex applications continue, so too will expectations for product quality and reliability. Behind every successful nasal product sits a delicate balance of interdependent elements. Formulation, […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.